Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assayD.J. McGrail,P.G. Pilié,N.U. Rashid, L. Voorwerk,M. Slagter,M. Kok,E. Jonasch,M. Khasraw, A.B. Heimberger,N.T. Ueno, R. Ferrarotto,J.T. Chang,S.-Y. LinAnnals of Oncology(2022)引用 2|浏览3暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要